Pacira BioSciences Overview
Pacira BioSciences (PCRX) has a P/E ratio of 70.07, above the Healthcare sector average of 26.85.
Get informed when a big investor buys or sells
+ Follow70.07
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Pacira BioSciences (PCRX) currently reports a P/E ratio of 70.07. That is above the Healthcare sector average of 26.85. Use the charts on this page to explore Pacira BioSciences's P/E ratio history and peer comparisons.
Pacira BioSciences's P/E ratio of 70.07 is higher than the Healthcare sector average of 26.85. That is roughly 161.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Pacira BioSciences's market price to a fundamental measure such as earnings, sales, or book value. At 70.07, PCRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 70.07, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Pacira BioSciences, and consider following PCRX for alerts when major investors trade the stock.
Pacira BioSciences is classified in the Healthcare sector. On P/E ratio, it currently shows 70.07 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PCRX with unrelated industries.
